SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Other Liabilities
SCI Pharmtech Inc
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Other Liabilities
NT$20.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Other Liabilities
NT$482.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
18%
|
CAGR 10-Years
3%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Other Liabilities
NT$119.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
2%
|
CAGR 10-Years
26%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Other Liabilities
NT$27.6m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-9%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Other Liabilities
NT$812.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
4%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Other Liabilities
NT$85.4m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-16%
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Other Liabilities?
Other Liabilities
20.6m
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Other Liabilities amounts to 20.6m TWD.
What is SCI Pharmtech Inc's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
0%
Over the last year, the Other Liabilities growth was -30%. The average annual Other Liabilities growth rates for SCI Pharmtech Inc have been 7% over the past three years , -1% over the past five years .
You don't have any saved screeners yet